MEDI MIX 1 by Meditech is a pharmaceutical-grade multi-compound anabolic blend combining Testosterone Phenylpropionate, Boldenone Undecylenate, and Testosterone Cypionate in a single oil-based injectable formulation. The inclusion of two testosterone esters with distinct release profiles alongside boldenone undecylenate represents a pharmacologically intentional combination, documented in anabolic research literature for its multi-phase androgenic activity and complementary mechanistic properties across constituent compounds.
 
✔ Key Research Insights
Studied for its multi-phase pharmacokinetic profile, with testosterone phenylpropionate contributing early androgen availability and testosterone cypionate providing sustained release in research subjects
Investigated for its effects on lean mass parameters and strength indices via androgen receptor activation across documented subject populations
Researched for the distinct contribution of boldenone undecylenate to nitrogen retention and erythropoietic stimulation, with documented effects on red blood cell production and vascular parameters in clinical observations
Examined for its influence on recovery markers and training adaptation in anabolic research literature
Documented for its relatively favorable androgenic-to-anabolic profile across constituent compounds, with boldenone undecylenate noted for low aromatization rates in comparative steroid pharmacology research
Manufactured by Meditech to pharmaceutical-grade purity and potency standards
 
📦 Product Specifications
Manufacturer: Meditech
Product: MEDI MIX 1
Molecules:
Testosterone Phenylpropionate: 50 mg/mL
Boldenone Undecylenate: 200 mg/mL
Testosterone Cypionate: 200 mg/mL
Total Concentration: 450 mg/mL
Appearance: Oil-based solution
Packing: Sterile 10 mL clear glass vial with red flip-off cap and labeled box
Dosage considerations may vary. Consulting a qualified professional is recommended.
 
⚙ How It Works
MEDI MIX 1 delivers three anabolic-androgenic compounds simultaneously via intramuscular injection, each contributing a distinct pharmacokinetic and pharmacodynamic profile in research subjects. Testosterone phenylpropionate, as a shorter-acting ester, undergoes relatively rapid enzymatic hydrolysis, contributing to early elevation of circulating free testosterone. Testosterone cypionate, as a longer-acting ester, provides a sustained androgen release phase extending across a more prolonged period, supporting stable serum testosterone concentrations between administrations. Boldenone undecylenate is a structurally modified testosterone derivative with a documented low aromatization rate and distinct pharmacological profile, investigated in research literature for its effects on nitrogen retention, appetite stimulation, and erythropoietic activity via increased erythropoietin production. The combined administration of these three compounds has been examined in anabolic research for potential synergistic effects on androgen receptor activation, protein synthesis, and nitrogen balance across study populations, while the varying ester lengths contribute to a more sustained and stable aggregate anabolic activity profile relative to single-compound preparations.
 
⭐ Product Overview
Manufactured by Meditech to pharmaceutical-grade purity and precision blending standards
Three-compound formulation with a pharmacologically intentional combination of complementary anabolic-androgenic agents at a total concentration of 450 mg/mL
Multi-phase pharmacokinetic profile attributed to the inclusion of both short- and long-acting testosterone esters alongside boldenone undecylenate
Supplied in a clearly labeled sterile glass vial with secure flip-off cap, consistent with pharmaceutical packaging standards
Widely referenced in anabolic pharmacology research under the testosterone phenylpropionate, boldenone undecylenate, and testosterone cypionate designations